Skip to content

Trial Summary

A Phase 3, multicentre, randomisated, open-label, active-controlled Study of Sotorasib and Panitumumab (Vectibix) vs investigator’s choice (Trifluridine and Tipiracil or Regorafenib) in previously treated metastatic CRC patients with the KRAS G12C mutation

Acronym:

CodeBreak 300

ACTRN/NCT /ethics:

NCT05198934

Scientific title:

Sotorasib and Panitumumab Versus Investigator’s Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak 300)

Sponsor / Cooperative group:

Amgen

Trial & Patient Characteristics

Cancer TypeBowel & colon
Trial TypeTreatment
PhasePhase III
Age Range18 years to 100 years
SexAll
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2022-04-29
Anticipated End Date2024-01-01

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Emailpamela.cooper@sa.gov.au
Phone08 8222 6140
Principal InvestigatorDr Timothy Price
Recruitment StatusNot Yet Recruiting